Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in the 2024 Bank of America Healthcare Conference to discuss their novel therapeutic for treating Alzheimer's disease. The event will take place on May 15, 2024, and can be accessed via a live webcast on their website.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has started the ALTITUDE-AD Phase 2 clinical trial of sabirnetug (ACU193) in early Alzheimer's Disease, representing a significant development in Alzheimer's research. This trial aims to evaluate the efficacy and safety of sabirnetug in patients with early AD, with promising Phase 1 results supporting its mechanism of action. The study will enroll approximately 540 patients with early AD and assess primary and secondary endpoints over 18 months.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report first quarter 2024 financial results on May 14, 2024. The company is focused on developing a novel therapeutic for Alzheimer's disease. A conference call and webcast will be held to provide a business and financial update.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.